Column Capital Advisors’s GSK GSK Stock Holding History

Column Capital Advisors’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$5.58K	Buy	154 +83	+117%	+$2.95K	﹤0.01%	589
2023 Q2	$2.53K	Hold	71	–	–	﹤0.01%	692
2023 Q1	$2.53K	Hold	71	–	–	﹤0.01%	703
2022 Q4	$2.5K	Buy	+71	New	+$2.37K	﹤0.01%	681
2022 Q3	–	Sell	-190	Closed	-$7.2K	–	728
2022 Q2	$10K	Hold	190	–	–	﹤0.01%	478
2022 Q1	$10K	Sell	190 -19	-9%	-$1.03K	﹤0.01%	503
2021 Q4	$12K	Buy	209 +25	+14%	+$1.3K	﹤0.01%	488
2021 Q3	$9K	Hold	184	–	–	﹤0.01%	481
2021 Q2	$9K	Buy	184 +88	+92%	+$4.23K	﹤0.01%	488
2021 Q1	$4K	Hold	96	–	–	﹤0.01%	552
2020 Q4	$4K	Sell	96 -88	-48%	-$4.04K	﹤0.01%	551
2020 Q3	$9K	Buy	184 +4	+2%	+$200	﹤0.01%	449
2020 Q2	$9K	Buy	180 +59	+49%	+$3.03K	﹤0.01%	488
2020 Q1	$6K	Buy	121 +30	+33%	+$1.6K	﹤0.01%	463
2019 Q4	$5K	Buy	+91	New	+$5.06K	﹤0.01%	525

Other funds holding GSK

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Column Capital Advisors's GSK Position: Q3 2023 in Review

Column Capital Advisors increased its GSK (GSK) stake by 117% in Q3 2023, buying an estimated $2.95K and bringing the position to 154 shares worth $5.58K. The position accounts for ﹤0.01% of the portfolio, ranked #589.

Column Capital Advisors first reported a position in GSK in Q4 2019 and has held it in 15 quarters since. The position peaked at $12K in Q4 2021. 846 funds tracked by Wall St. Rank hold GSK as of Q3 2023.

Column Capital Advisors held 154 shares of GSK worth $5.58K as of Q3 2023.
Column Capital Advisors bought 83 GSK shares in Q3 2023, an estimated $2.95K.
GSK made up ﹤0.01% of Column Capital Advisors's portfolio in Q3 2023, its #589 holding.
Column Capital Advisors first reported a position in GSK in Q4 2019 and has held it in 15 quarters since.
Column Capital Advisors's GSK position peaked at $12K in Q4 2021.
846 funds tracked by Wall St. Rank held GSK as of Q3 2023.

Based on Column Capital Advisors's 13F filing for Q3 2023, filed 3 Nov 2023.